The role of healthcare providers in accompanying biosimilars in inflammatory bowel diseases

Click to increase image sizeClick to decrease image size

Declaration of interest

C Felice: consultancy or advisory board member for AbbVie and MSD. D Pugliese: consultancy or lectur fee from Abbvie, Takeda, MSD. A Armuzzi: consultant for AbbVie, Allergan, Amgen, Biogen, Celgene, Celltrion, Ferring, Hospira, Janssen, Lilly, MSD, Mundipharma, Mylan, Pfizer, Samsung Bioepis, Sandoz, Sofar, Takeda. Lecture fees: AbbVie, Amgen, AstraZeneca, Chiesi, Ferring, Hospira, Janssen, Medtronic, MSD, Mitsubishi Tanabe, Mundipharma, Nikkiso, Otsuka, Pfizer, Samsung Bioepis, Takeda, Tigenix, Zambon. Research grants: MSD, Takeda, Pfizer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial relationships or otherwise to disclose.

Additional information

Funding

This paper was not funded.